Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1799 results
September 2019
-
Media ReleaseNovartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent…
-
Media ReleaseNovartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraineThe 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years…
-
Media ReleaseNovartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancerCurrently, there are no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a particularly aggressive form of the diseaseBreakthrough Therapy…
-
Media ReleaseNovartis study shows migraine support in the workplace can improve employee quality of lifeResults from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1] …
-
Media ReleaseSandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicineWorldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS…
-
Media ReleaseEntresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findingsResults from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1…
-
Media ReleaseNovartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpointEntresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
August 2019
-
Living with HFpEF – a patient’s story
Cynthia lives with Heart Failure with preserved Ejection Fraction, a complex and challenging condition.
-
Key ReleaseNovartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studiesIn ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary…
-
Featured NewsBlood Cancer Awareness Month - Cutting Edge Innovation in Hematology
Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
-
Featured NewsImpact Measurement and Valuation
Novartis joins seven global companies to found the Value Balancing Alliance
-
Media ReleaseNovartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will…
Pagination
- ‹ Previous page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- …
- 150
- › Next page